Solid Biosciences SLDB
NASDAQ SLDB
$6.39 -0.01 (-0.08%)
As of: Oct 21, 2026 · 3:59 PM EDT

Solid Biosciences (SLDB) FCF Margin (2022)

Updated

Solid Biosciences' FCF Margin was -1247.74% in FY2022, down 667.38 percentage points from -580.36% in FY2021.

Analysis

Solid Biosciences (SLDB) FCF Margin (2022) Analysis & Trends

  • Per Business Quant data, FCF Margin in earlier years was -580.36% in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 33.76%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 28.82%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 18.33%
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 26.96%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 38.60%
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 6.55%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 34.70%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 44.00%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 2.01%
10 Solid Biosciences 921.04 Mn -261.31 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2022 -275.80%
API Access

Solid Biosciences FCF Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=fcf-margin&ticker=SLDB&period=max&api_key=YOUR_API_KEY